European and U.S. regulators are reviewing the safety of Gilead Sciences' leukaemia drug Zydelig due to concerns over serious adverse events, including deaths. The actions were prompted by an increased rate of harmful events, mostly due to infections, seen in three clinical trials that tested the drug in combination with other cancer medicines, the European Medicines Agency said on Friday.